cellulitis_erysipelas
CELLULITIS/ERYSIPELAS
Cellulitis is a spreading bacterial skin infection that infects deeply involving the subcutaneous tissues.
It typically occurs in areas where the skin integrity has been compromised.
It may also result from blood-borne spread of infection to the skin and subcutaneous tissues.
It is commonly caused by beta-hemolytic streptococci and Staphylococcus aureus.
Erysipelas is a type of cellulitis with margins that are sharply demarcated, involves the epidermis and superficial lymphatics.
Onset of symptoms is acute whereas cellulitis has an indolent course.
It is more commonly caused by beta-hemolytic streptococci.

Prevention

Prophylaxis

  • Predisposing factors should be identified and removed if possible 
  • Preventive measures may be helpful in reducing recurrent skin infections
    • Staphylococcal infection: Oral Clindamycin
    • Beta-hemolytic streptococcal infection: Penicillin or Erythromycin for 4-52 weeks or Benzathine penicillin intramuscular (IM) injections every 2-4 weeks
    • Treatment may be continued for several months with interval relapse assessment
Editor's Recommendations
Most Read Articles
Yesterday
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
5 days ago
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).
Pearl Toh, 3 days ago
It takes just less than 4 days for COVID-19 to spread from one person to another and cause symptoms, and more than 10 percent of the cases are infected by a person who has caught the virus but yet to show symptoms, recent studies suggest.
Audrey Abella, 4 days ago
A prospective study has shown the potential of a new algorithm – the FibroScan-AST (FAST) score – to identify patients with nonalcoholic steatohepatitis (NASH) with significant activity and fibrosis.